Compare ASLE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | TRDA |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.5M | 274.5M |
| IPO Year | 2018 | 2021 |
| Metric | ASLE | TRDA |
|---|---|---|
| Price | $6.09 | $7.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 464.5K | 294.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $335,286,000.00 | $25,421,000.00 |
| Revenue This Year | $23.41 | $39.97 |
| Revenue Next Year | $6.80 | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $4.93 |
| 52 Week High | $9.08 | $16.45 |
| Indicator | ASLE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 49.88 |
| Support Level | $6.08 | $5.75 |
| Resistance Level | $6.75 | $10.82 |
| Average True Range (ATR) | 0.29 | 0.51 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 0.00 | 60.57 |
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.